Final Word - BioPharm International


Final Word

Biosimilar Developers Face a Reference-Product Dilemma

March 1, 2012

Does global development have to entail multiple comparability studies?

Saving the Next Generation of Regulatory Scientists

February 1, 2012

New educational programs are key to the industry's future and to safe, available drugs.

USAID Moves Global Healthcare Initiatives Forward

January 1, 2012

Government plans require investment, partnership, and industry collaboration.

The Case for Pediatric Exclusivity

December 1, 2011

Reauthorization of pediatric exclusivity provisions looms in 2012 and debates begin anew.

The Economic Challenge of Prescription–Diagnostic Combinations

November 1, 2011

With the rise in therapeutics comes more complex partnerships.

How to Choose the Right CMO

October 1, 2011

Knowing in advance what you need can make a huge difference in a sponsor company's success.

Advocating for Biosimilar Approval Standards Under BPCI

September 1, 2011

FDA weighs multiple views regarding the Biologics Price Competition and Innovation Act.

Biopharmaceutical High Performance

August 1, 2011

Industry may be its own obstacle to success in achieving the desired high-performance state.

The Status of the DNA Vaccine Field

July 1, 2011

Plasmid DNA-encoding proteins offer many advantages, which are now being used in clinical trials.



Click here